Every Form 4 that Dyne Therapeutics, Inc. (DYN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DYN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DYN filings page.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 904 shares of common stock on March 5, 2026 at $14.90 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a pre-arranged Rule 10b5-1 "binding contract," so the transaction was not a discretionary trade. Following this sale, he beneficially owned 171,606 shares, including 153,625 unvested RSUs.
Dyne Therapeutics, Inc. CEO and President John Cox reported an automatic sale of 2,732 shares of common stock on March 5, 2026 at $14.90 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024 under a pre-established Rule 10b5-1 “binding contract,” so the sale is not described as a discretionary trade.
After this transaction, Cox directly holds 374,145 shares of common stock, which the filing states includes 279,895 unvested RSUs. In addition, 18,000 shares are held in each of four separate trusts for the benefit of a child of the reporting person, reported as indirect ownership positions.
Dyne Therapeutics CEO and President John Cox reported new equity awards in the company’s stock. On February 12, 2026, he received 180,000 shares of common stock in the form of restricted stock units that vest quarterly over four years starting May 12, 2026.
He was also granted a stock option for 285,000 shares of common stock at an exercise price of $16 per share, vesting in equal monthly installments over four years through February 12, 2030. Following these awards, he directly beneficially owns 376,877 shares of common stock, which include unvested RSUs.
Additional holdings of 18,000 shares of common stock in each of four separate trusts are reported as indirect ownership, with each trust held for the benefit of a child of the reporting person.
Dyne Therapeutics Chief Medical Officer Kerr Douglas reported new equity awards in the company. On February 12, 2026, Douglas received 85,000 shares of Common Stock in the form of restricted stock units, bringing direct beneficial ownership of Common Stock to 172,510 shares, including 156,625 unvested RSUs.
Douglas was also granted a stock option for 130,000 shares of Common Stock at an exercise price of $16 per share. The option is scheduled to vest in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.
Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer reported new equity awards in the company’s stock. On February 12, 2026, she received 60,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share, bringing her directly owned Common Stock to 154,729 shares, including 132,152 unvested RSUs.
She was also granted a stock option for 90,000 shares of Common Stock at an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.
Dyne Therapeutics’ Chief Financial Officer Erick Lucera received new equity awards. On February 12, 2026, Lucera was granted 65,000 restricted stock units, each representing one share of common stock, at a grant price of $0. These RSUs are scheduled to vest in equal quarterly installments over four years starting May 12, 2026.
On the same date, Lucera also received a stock option covering 105,000 shares of common stock with an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030. Following the RSU grant, Lucera directly beneficially owns 131,100 unvested RSUs.
Dyne Therapeutics CEO and President, who is also a director, reported selling 2,662 shares of Common Stock on December 5, 2025 at a weighted average price of $20.72. The shares were automatically sold to satisfy tax withholding obligations tied to restricted stock units granted on December 4, 2024, under a restricted stock unit agreement that constitutes a binding contract consistent with the affirmative defense to liability under Rule 10b5-1, so the sale did not represent a discretionary trade.
After this transaction, the insider beneficially owns 196,877 shares directly, including 108,976 unvested RSUs, and 18,000 shares held in each of four trusts for the benefit of the reporting person’s children. The report notes that 2,662 shares were matchable under Section 16(b) with a prior purchase of 100,000 shares on July 14, 2025, and the reporting person has paid the issuer $31,111.88, representing the profit deemed realized on that short-swing transaction.